Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated: April 1, 2026, 5:00 am
Author: Getaka|Social: XLinkedIn
Stock Ticker - BSE: 541299 | NSE: DLCL

Dr Lalchandani Labs Ltd: Intrinsic Value & Share Price Analysis

Fair Value

₹8.03Overvalued by 45.74%vs CMP ₹14.80

P/E (27.3) × ROE (3.1%) × BV (₹11.70) × DY (2.00%)

₹8.17Overvalued by 44.80%vs CMP ₹14.80
MoS: -81.2% (Negative)Confidence: 59/100 (Moderate)Models: 1 Under, 7 Over
ModelCategoryValueWeightSignal
PE-ROEEarnings₹7.0026%Over (-52.7%)
Graham NumberEarnings₹11.9218%Over (-19.5%)
DCFCash Flow₹0.0615%Over (-99.6%)
Net Asset ValueAssets₹11.748%Over (-20.7%)
EV/EBITDAEnterprise₹8.4910%Over (-42.6%)
Earnings YieldEarnings₹5.408%Over (-63.5%)
ROCE CapitalReturns₹19.608%Under (+32.4%)
Revenue MultipleRevenue₹5.156%Over (-65.2%)
Consensus (8 models)₹8.17100%Overvalued
Key Drivers: ROE 3.1% is below cost of equity. | Wide model spread (₹0–₹20) — high uncertainty.

PE-ROE · Graham · EPV · DCF · NAV · EV/EBITDA · DDM · Earnings Yield · ROCE Capital · Revenue Multiple | CoE: 12% · Terminal: 4% · EPS CAGR: -12.8%

*Investments are subject to market risks

Investment Snapshot

43
Dr Lalchandani Labs Ltd scores 43/100 (Weak)
Based on 5 dimensions: health, institutional flow, earnings quality, momentum, and peer comparison
Stock Health50/100 · Moderate
ROCE 2.8% WeakROE 3.1% WeakD/E 0.35 ModerateInterest Coverage 0.0x RiskyProfitable 4/5 years Consistent
Smart Money60/100 · Moderate
Promoter increased by 1.75% Positive
Earnings Quality40/100 · Moderate
OPM stable around 13% SteadyWorking capital: 157 days Capital intensive
Quarterly Momentum35/100 · Weak
Revenue (4Q): -22% YoY Declining
Industry Rank35/100 · Weak
P/E 27.3 vs industry 103.6 Cheaper than peersROCE 2.8% vs industry 10.6% Below peersROE 3.1% vs industry 10.7% Below peers3Y sales CAGR: -27% Shrinking

Weights: Health 30% · Earnings Quality 25% · Momentum 20% · Industry Rank 15% · Smart Money 10%. Scores are computed from reported financials and recalculated daily. Not investment advice.

Share Price and Basic Stock Data

Last Updated: April 1, 2026, 5:00 am

Market Cap 12.8 Cr.
Current Price 14.8
Intrinsic Value₹8.17
High / Low 21.2/8.15
Stock P/E27.3
Book Value 11.7
Dividend Yield0.00 %
ROCE2.81 %
ROE3.08 %
Face Value 10.0
PEG Ratio-2.14

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Dr Lalchandani Labs Ltd

Competitors

Stock Name ⇩Market Cap ⇩Current Price ⇩High / Low ⇩Stock P/E ⇩Book Value ⇩Dividend Yield ⇩ROCE ⇩ROE ⇩Face Value ⇩
Dr Lalchandani Labs Ltd 12.8 Cr. 14.8 21.2/8.1527.3 11.70.00 %2.81 %3.08 % 10.0
Asarfi Hospital Ltd 348 Cr. 177 221/72.920.7 45.20.00 %15.8 %14.1 % 10.0
Narayana Hrudayalaya Ltd 33,417 Cr. 1,635 2,372/1,38040.5 1990.28 %20.8 %24.2 % 10.0
Lotus Eye Hospital & Institute Ltd 212 Cr. 102 148/62.0326 29.20.00 %2.99 %1.22 % 10.0
Industry Average11,325.67 Cr482.20103.6371.280.07%10.60%10.65%10.00

All Competitor Stocks of Dr Lalchandani Labs Ltd

Quarterly Result

MetricSep 2019Mar 2020Sep 2020Mar 2021Sep 2021Mar 2022Sep 2022Mar 2023Sep 2023Mar 2024Sep 2024Mar 2025Sep 2025
Sales 3.033.072.717.078.023.262.282.762.732.082.132.332.05
Expenses 2.302.532.145.406.072.812.462.502.381.041.591.821.79
Operating Profit 0.730.540.571.671.950.45-0.180.260.351.040.540.510.26
OPM % 24.09%17.59%21.03%23.62%24.31%13.80%-7.89%9.42%12.82%50.00%25.35%21.89%12.68%
Other Income 0.000.000.000.000.000.000.010.000.000.240.000.000.29
Interest 0.090.090.050.300.240.330.480.510.110.280.050.030.01
Depreciation 0.210.220.230.290.280.300.330.340.330.290.280.280.28
Profit before tax 0.430.230.291.081.43-0.18-0.98-0.59-0.090.710.210.200.26
Tax % 0.00%82.61%24.14%27.78%25.17%-22.22%0.00%0.00%0.00%0.00%23.81%-35.00%26.92%
Net Profit 0.430.040.230.791.07-0.13-0.97-0.59-0.090.710.150.270.20
EPS in Rs 0.490.050.260.911.23-0.15-1.11-0.68-0.100.820.170.310.23

Last Updated: February 2, 2026, 6:16 am

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: February 27, 2026, 4:25 am

MetricMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales 2.795.266.109.7811.285.044.814.454.38
Expenses 2.174.064.847.548.814.954.593.523.61
Operating Profit 0.621.201.262.242.470.090.220.930.77
OPM % 22.22%22.81%20.66%22.90%21.90%1.79%4.57%20.90%17.58%
Other Income 0.030.010.000.000.000.001.400.130.29
Interest 0.160.140.180.350.600.990.380.090.04
Depreciation 0.130.350.420.520.590.660.620.560.56
Profit before tax 0.360.720.661.371.28-1.560.620.410.46
Tax % 25.00%26.39%28.79%26.28%28.12%0.00%0.00%-2.44%
Net Profit 0.260.530.471.010.93-1.560.620.420.47
EPS in Rs 0.440.610.541.161.07-1.790.710.480.54
Dividend Payout % 0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2018-20192019-20202020-20212021-20222022-20232023-20242024-2025
YoY Net Profit Growth (%)103.85%-11.32%114.89%-7.92%-267.74%139.74%-32.26%
Change in YoY Net Profit Growth (%)0.00%-115.17%126.21%-122.81%-259.82%407.49%-172.00%

Dr Lalchandani Labs Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 7 years from 2018-2019 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:%
5 Years:-6%
3 Years:-27%
TTM:-7%
Compounded Profit Growth
10 Years:%
5 Years:-2%
3 Years:-23%
TTM:155%
Stock Price CAGR
10 Years:%
5 Years:19%
3 Years:0%
1 Year:21%
Return on Equity
10 Years:%
5 Years:0%
3 Years:-7%
Last Year:4%

Last Updated: September 5, 2025, 3:16 pm

Balance Sheet

Last Updated: December 4, 2025, 2:46 am

MonthMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital 2.934.334.334.334.334.334.334.334.33
Reserves 0.403.734.215.226.154.595.215.625.82
Borrowings 1.880.901.764.045.156.403.484.074.58
Other Liabilities 1.001.181.631.612.492.401.971.721.36
Total Liabilities 6.2110.1411.9315.2018.1217.7214.9915.7416.09
Fixed Assets 2.063.283.475.245.755.393.993.513.38
CWIP 0.000.000.000.000.000.000.000.000.00
Investments 0.240.240.240.240.240.240.410.270.27
Other Assets 3.916.628.229.7212.1312.0910.5911.9612.44
Total Assets 6.2110.1411.9315.2018.1217.7214.9915.7416.09

Reserves and Borrowings Chart

Cash Flow

MonthMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity + 0.58-0.45-0.101.192.010.00-0.220.37
Cash from Investing Activity + -1.29-1.95-0.53-2.26-1.53-0.201.000.06
Cash from Financing Activity + 1.573.510.851.710.16-0.23-1.590.58
Net Cash Flow 0.851.120.230.640.64-0.43-0.811.01
Free Cash Flow -0.73-2.39-0.71-1.100.91-0.300.740.30
CFO/OP 94%-32%5%67%95%0%-100%40%

Free Cash Flow

MonthMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Free Cash Flow-1.260.30-0.50-1.80-2.68-6.31-3.26-3.14

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days 149.14126.99199.25148.54136.55359.93356.65431.44
Inventory Days 167.03233.36158.7068.75191.07458.51255.15490.47
Days Payable 426.86406.89355.4897.06175.15404.21217.94365.00
Cash Conversion Cycle -110.69-46.542.47120.23152.47414.23393.86556.91
Working Capital Days 162.22167.23206.43104.5077.98188.29163.91156.66
ROCE %12.14%8.72%14.40%12.87%-3.68%-2.68%2.81%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthSep 2020Mar 2021Sep 2021Mar 2022Sep 2022Mar 2023Sep 2023Mar 2024Sep 2024Mar 2025Sep 2025Mar 2026
Promoters 60.78%60.78%60.78%60.78%60.78%60.78%60.78%60.78%57.18%48.32%31.15%32.90%
Public 39.22%39.22%39.22%39.22%39.23%39.22%39.21%39.22%42.82%51.68%68.84%67.11%
No. of Shareholders 143143151157162164159165181246206234

Shareholding Pattern Chart

No. of Shareholders

Dr Lalchandani Labs Ltd: Intrinsic Value & Share Price Analysis - Shareholder trend analysis

This stock is not held by any mutual fund.

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 25Mar 24Mar 23Mar 22Mar 21
FaceValue 10.0010.0010.0010.0010.00
Basic EPS (Rs.) 0.961.43-3.612.152.33
Diluted EPS (Rs.) 0.961.43-3.612.152.33
Cash EPS (Rs.) 2.272.87-2.083.513.52
Book Value[Excl.RevalReserv]/Share (Rs.) 22.9421.9820.5624.1622.01
Book Value[Incl.RevalReserv]/Share (Rs.) 22.9822.0220.5924.2022.04
Revenue From Operations / Share (Rs.) 10.2811.1011.6326.0322.57
PBDIT / Share (Rs.) 2.151.000.205.555.12
PBIT / Share (Rs.) 0.84-0.43-1.334.203.93
PBT / Share (Rs.) 0.921.43-3.612.973.18
Net Profit / Share (Rs.) 0.961.43-3.612.152.33
PBDIT Margin (%) 20.899.041.7521.3322.68
PBIT Margin (%) 8.22-3.93-11.4016.1217.41
PBT Margin (%) 9.0312.83-31.0011.4114.08
Net Profit Margin (%) 9.3612.83-31.008.2710.34
Return on Networth / Equity (%) 4.196.48-17.548.9110.60
Return on Capital Employeed (%) 3.63-1.89-4.6313.7113.81
Return On Assets (%) 2.644.11-8.825.146.65
Long Term Debt / Equity (X) 0.000.020.370.250.27
Total Debt / Equity (X) 0.400.350.520.380.35
Asset Turnover Ratio (%) 0.280.290.280.670.72
Current Ratio (X) 1.921.882.072.222.98
Quick Ratio (X) 1.691.601.781.902.75
Inventory Turnover Ratio (X) 3.260.000.000.000.00
Interest Coverage Ratio (X) 10.901.130.084.526.81
Interest Coverage Ratio (Post Tax) (X) 4.46-0.49-0.582.754.10
Enterprise Value (Cr.) 5.207.9213.8914.816.53
EV / Net Operating Revenue (X) 1.171.652.761.310.66
EV / EBITDA (X) 5.5818.19157.326.152.94
MarketCap / Net Operating Revenue (X) 0.991.422.441.270.61
Price / BV (X) 0.440.711.381.370.63
Price / Net Operating Revenue (X) 0.991.422.441.270.61
EarningsYield 0.090.09-0.120.060.16

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

About the Company - Qualitative Analysis

Dr. Lalchandani Labs Ltd. is a Public Limited Listed company incorporated on 02/08/2017 and has its registered office in the State of Delhi, India. Company's Corporate Identification Number(CIN) is L85320DL2017PLC321605 and registration number is 321605. Currently Company is involved in the business activities of Activities of independent diagnostic/pathological laboratories. Company's Total Operating Revenue is Rs. 4.45 Cr. and Equity Capital is Rs. 4.33 Cr. for the Year ended 31/03/2025.
INDUSTRYADDRESSCONTACT
Hospitals & Medical ServicesM-20, Basement, Greater Kailash, New Delhi Delhi 110048Contact not found
Management
NamePosition Held
Dr. Arjan Lal ChandaniChairman & Managing Director
Mr. Mohit Lal ChandaniWholeTime Director & CEO
Mrs. Anchal GuptaExecutive Director & CFO
Mrs. Swati ChandraNon Executive Director
Mr. Rajiv HandaIndependent Director
Mr. Mohan Lal GandhiIndependent Director

FAQ

What is the intrinsic value of Dr Lalchandani Labs Ltd and is it undervalued?

As of 14 April 2026, Dr Lalchandani Labs Ltd's intrinsic value is ₹8.17, which is 44.80% lower than the current market price of ₹14.80, suggesting the stock is overvalued. This is calculated using the PE ratio method factoring in ROE (3.08 %), book value (₹11.7), dividend yield (0.00 %), and 5-year EPS CAGR.

What is the current share price and 52-week range of Dr Lalchandani Labs Ltd?

Dr Lalchandani Labs Ltd is trading at ₹14.80 as of 14 April 2026, with a FY2026-2027 high of ₹21.2 and low of ₹8.15. The stock is currently in the middle of its 52-week range. Market cap stands at ₹12.8 Cr..

How does Dr Lalchandani Labs Ltd's P/E ratio compare to its industry?

Dr Lalchandani Labs Ltd has a P/E ratio of 27.3, which is below the industry average of 103.63. Trading at a steep discount to peers could signal a value opportunity or reflect concerns about the company's fundamentals.

Is Dr Lalchandani Labs Ltd financially healthy?

Key indicators for Dr Lalchandani Labs Ltd: ROCE of 2.81 % is on the lower side compared to the industry average of 10.60%; ROE of 3.08 % is below ideal levels (industry average: 10.65%). Dividend yield is 0.00 %.

Is Dr Lalchandani Labs Ltd profitable and how is the profit trend?

Dr Lalchandani Labs Ltd reported a net profit of ₹0 Cr in Mar 2025 on revenue of ₹4 Cr. Compared to ₹1 Cr in Mar 2022, the net profit shows a declining trend.

Does Dr Lalchandani Labs Ltd pay dividends?

Dr Lalchandani Labs Ltd has a dividend yield of 0.00 % at the current price of ₹14.80. The company is currently not paying meaningful dividends.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Dr Lalchandani Labs Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE
Explore Industry-wise Stock Analysis Reports